Halozyme Therapeutics Inc.

+0.19 (+0.46%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.92B
Current PE25.90
Forward PE 25.22
2yr Forward PE 16.13
See more stats
Estimates Current Quarter
Revenue$107.04 Million
Adjusted EPS$0.43
See more estimates
10-Day MA$41.52
50-Day MA$41.33
200-Day MA$43.83
See more pivots

Halozyme Therapeutics Inc. Stock, NASDAQ:HALO

11388 Sorrento Valley Road, San Diego, California 92121
United States of America
Phone: +1.858.794.8889
Number of Employees: 136


Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.